Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
132 Leser
Artikel bewerten:
(0)

Research and Markets - Global $1.5 Billion CRISPR/Cas9 Market Outlook, 2022: Major Players Include Thermo Fisher Scientific, Lonza, Agilent Technologies, GenScript, Editas Medicine & Horizon Discovery

DUBLIN, October 18, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global CRISPR/Cas9 Market Outlook 2022" report to their offering.

It is anticipated that the global CRISPR/Cas9 market will cross US$ 1.5 Billion by 2022

The growth of the market is likely to be driven by expanding drug discovery applications and increasing research related activities for exploring CRISPR/Cas9 therapeutic applications.

The report, Global CRISPR/Cas9 Market Outlook 2022, provides an insight into the current and future prospective of this market. This report covers the major opportunities in this area, and drivers that have impact on the market. The report also discusses some of the challenges currently faced by the market.

The major application areas of CRISPR/Cas9 include cell line engineering, genetic engineering, CRISPR plasmid development, human stem cells, gene library development and producing GM organisms or crops. Cell Line Engineering is the largest area of application of CRISPR/Cas9, followed by Genetic Engineering. This large share can be attributed to extensibility and multiplexity of CRISPR/Cas9 in modifying the multiple sites within the mammalian genome. The genetic engineering market employing CRISPR/Cas9 is expected to witness the highest growth in 2016-2022. This growth is likely to be driven by reduction of evolutionary time in comparison to previous gene editing tools, such as Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs).

The last segment of the report is entirely devoted to profiling leading companies of the CRISPR/Cas9 industry, including some major players like Thermo Fisher Scientific, Lonza, Agilent Technologies, GenScript, Editas Medicine, Horizon Discovery, etc.

This segment provides access to the financials, product portfolio, and recent developments of these companies. This segment also discusses the strengths and weaknesses of key players in this industry. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global CRISPR/Cas9 market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Introduction to CRISPR/Cas9 Genome Editing

4. Market Dynamics

4.1 Market Drivers

4.1.1 Expanding Drug Discovery Market

4.1.2 Surging Demand for Synthetic Genes

4.1.3 Rising Prevalence of Genetic Disorders

4.1.4 Increasing Investments

4.2 Market Challenges

4.2.1 Ethical Issues Concerning Misuse of CRISPR Gene Editing Tool

4.2.2 Presence of Alternative Gene Editing Tools

4.3 Market Opportunities

4.3.1 Increasing Usage of CRISPR Gene Editing for Gene Surgery

4.3.2 Enhancing Plant Immunity with CRISPR/Cas9

4.3.3 Emerging Contract Research Market for CRISPR/Cas9

5. Global CRISPR/Cas9 Market Outlook to 2022

6. CRISPR/Cas9 Market by Application

6.1 Cell Line Engineering

6.2 Genetic Engineering

6.3 CRISPR Plasmid

6.4 Gene Library

6.5 Human Stem Cells

6.6 Genetically Modified (GM) Organisms/Crops

7. CRISPR/Cas9 Market by End User

7.1 Academic & Research Institutes

7.2 Pharma/Biotech Companies

7.3 Others

8. CRISPR/Cas9 Market by Geography

9. Mergers and Collaborations

10. Company Profiles

10.1 GE Healthcare

10.2 Thermo Fisher Scientific, Inc.

10.3 Agilent Technologies, Inc.

10.4 Lonza

10.5 GenScript

10.6 Horizon Discovery Group plc.

10.7 Editas Medicine, Inc.

10.8 CRISPR Therapeutics

10.9 Caribou Biosciences, Inc.

10.10 Intellia Therapeutics, Inc.

10.11 Integrated DNA Technologies

10.12 OriGene Technologies, Inc.

10.13 Transposagen Biopharmaceuticals, Inc.

10.14 New England Biolabs Inc.

For more information about this report visit http://www.researchandmarkets.com/research/dsj9jw/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.